What is Aminocaproic Acid?
Aminocaproic acid, also known as ε-aminocaproic acid (EACA), is a synthetic derivative of the amino acid lysine. It is primarily used as an antifibrinolytic agent to inhibit the breakdown of fibrin, a protein involved in blood clotting. This makes it useful in treating conditions associated with excessive bleeding.
Chemical Structure and Properties
Chemical Formula: C6H13NO2
Molecular Weight: 131.17 g/mol
Appearance: White crystalline powder
Solubility: Soluble in water and slightly soluble in ethanol
Mechanism of Action
Aminocaproic acid works by inhibiting the activation of plasminogen to plasmin, an enzyme responsible for breaking down fibrin clots. By blocking this process, aminocaproic acid helps to stabilize blood clots and reduce bleeding.
Applications of Aminocaproic Acid
1. Medical Applications
Bleeding Disorders
Hemophilia: Used to prevent and treat bleeding episodes in patients with hemophilia by stabilizing clot formation.
Surgical Procedures: Administered during or after surgery to reduce bleeding and the need for blood transfusions, particularly in cardiac, liver, and orthopedic surgeries.
Menorrhagia: Used to manage heavy menstrual bleeding by promoting clot stability.
Dental Procedures
Trauma and Emergency Situations
2. Other Potential Applications
Antifibrinolytic Therapy
Benefits of Aminocaproic Acid
Effective Bleeding Control: Reduces the need for blood transfusions and stabilizes clots effectively.
Versatile Use: Applicable in various medical scenarios, including surgeries, trauma care, and treatment of bleeding disorders.
Rapid Action: Quickly inhibits fibrinolysis, making it suitable for emergency situations.
Side Effects
Common Side Effects: Nausea, vomiting, diarrhea, muscle weakness, and dizziness.
Serious Side Effects: Rare but may include thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism), hypotension, and renal impairment.
Dosage and Administration
Dosage: The dosage varies depending on the condition being treated. It can be administered orally, intravenously, or topically, depending on the clinical scenario.
Monitoring: Patients receiving aminocaproic acid should be monitored for signs of thrombosis and renal function.
Package
![](https://www.chemicalbook.com/ProductImageEN/2021-05-27/6375772668597981071237600.jpg)
Shipping
![](https://www.chemicalbook.com/ProductImageEN/2021-05-27/6375772278497296547457723.jpg)
Company informations
![](https://www.chemicalbook.com/ProductImageEN/2021-05-27/6375772280295935201129376.jpg)
Contact information